Syfovre-related vision loss has been reported in patients after the first time they used a Syfovre injection treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). In mid-July 2023 the American Society of Retinal Specialists (ASRS) issued a warning letter about Syfovre-related vision loss as well as some other … [Read more...]
Syfovre Retinal Vasculitis Cases Warning Letter July 2023
The American Society of Retinal Specialists (ASRS) issued a warning letter about the Syfovre retinal vasculitis cases in patients who used this injection eye drug. Syfovre is a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Occlusive retinal vasculitis is a type of eye inflammation that blocks blood flow … [Read more...]
Ozempic Safety Issues Update: July 2023 Edition
In this Ozempic safety issues update we report on thyroid cancer, gallbladder disease, and suicidal thoughts as being possible Ozempic side effects. The European Medicines Agency (EMA) recently announced it has begun an investigation into Ozempic and suicidal thoughts as well as self-harm. From July 11, 2023 document “EMA statement on ongoing … [Read more...]
Georgia-Pacific Is Litigation-Protected After Unit’s Bankruptcy
Georgia-Pacific LLC can avoid tort lawsuits tied to certain products while its affiliate, Bestwall LLC, seeks to resolve those claims in bankruptcy, the Fourth Circuit ruled. The US Bankruptcy Court for the Western District of North Carolina, which is overseeing Bestwall’s Chapter 11 case, had “related to” jurisdiction to issue a preliminary … [Read more...]
Manufactured doubt and the EPA 2020 chrysotile asbestos risk assessment
While all forms of asbestos have been determined to be carcinogenic to humans by the International Agency for Research on Cancer (IARC) as well as other authoritative bodies, the relative carcinogenic potency of chrysotile continues to be argued, largely in the context of toxic tort litigation. Relatively few epidemiologic studies have investigated … [Read more...]
Ozempic Gallbladder Cases: Gallbladder Disease and Gallbladder Removal
The use of Ozempic has been associated with gallbladder diseases such as gallstones (cholelithiasis) and inflammation of the gallbladder (cholecystitis). These Ozempic side effects can lead to gallbladder removal surgery (cholecystectomy). We are currently investigating certain Ozempic gallbladder cases as possible Ozempic drug injury lawsuits that … [Read more...]
Trulicity Double-Dose Recall in 2021 is Still a Drug Safety Issue in 2023
There was a relatively “low profile” Trulicity double-dose recall by Eli Lilly & Company back in 2021. Because there may still be thousands of double-dose Trulicity injectors in patients’ homes, we are concerned that this is an ongoing Trulicity drug safety issue. Here are seven reasons why: Some Trulicity autoinjector devices labeled as … [Read more...]
Merck reports positive data from malignant pleural mesothelioma trial
Merck and the Canadian Cancer Trials Group (CCTG) have reported positive data from the Phase II/III CCTG IND.227/KEYNOTE-483 trial of Keytruda, along with chemotherapy, as first-line treatment for advanced malignant pleural mesothelioma patients. The open-label, randomised Phase II/III trial has been designed for assessing the combination of … [Read more...]
Does the Presence of Asbestos-Containing Materials in Buildings Post-construction and Before Demolition Have an Impact on the Exposure to Occupants in Non-occupational Settings?
Abstract This narrative review aims to determine if asbestos-containing materials in buildings pose a hazard to building occupants in non-occupational settings. This paper is limited to the post-construction and pre-demolition stages of a building. The researchers selected 19 studies from the 126 studies screened, concerning exposure to asbestos … [Read more...]
Prolia Side Effect: Hypocalcemia in Patients on Dialysis
This relatively new Prolia side effect, hypocalcemia, first came to our attention in late 2022 with the release of this November 22, 2022 document, “FDA Drug Safety Communication: FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)”. From that November 2022 FDA Drug Safety … [Read more...]
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 22
- Next Page »